Experimental Dermatology
Pathogenic DST sequence variants result in either epidermolysis bullosa simplex (EBS) or hereditary sensory and autonomic neuropathy type 6 (HSAN‐VI)
Experimental Dermatology, Volume 31, Issue 6, Page 949-955, June 2022.
Experimental Dermatology
CircEIF5 contributes to hyperproliferation and inflammation of keratinocytes in psoriasis via p‐NFκB and p‐STAT3 signalling pathway
Experimental Dermatology, Volume 31, Issue 8, Page 1145-1153, August 2022.
Experimental Dermatology
Autologous lipoaspirate as a new treatment of vulvar lichen sclerosus: A review on literature
Experimental Dermatology, EarlyView.
Experimental Dermatology
Hidradenitis suppurativa: Morphologic and vascular study of nodular inflammatory lesions by means of optical coherence tomography
Experimental Dermatology, Volume 31, Issue 7, Page 1076-1082, July 2022.
Experimental Dermatology
Impact of psychiatric comorbidities in psoriasis, hidradenitis suppurativa and atopic dermatitis: The importance of a psychodermatological approach
Experimental Dermatology, Volume 31, Issue 6, Page 956-961, June 2022.
Experimental Dermatology
Omaveloxolone attenuates squamous cell carcinoma growth and disease severity in an Epidermolysis Bullosa mouse model
Experimental Dermatology, Volume 31, Issue 7, Page 1083-1088, July 2022.
Experimental Dermatology
Genes and compounds that increase type VII collagen expression as potential treatments for dystrophic epidermolysis bullosa
Experimental Dermatology, Volume 31, Issue 7, Page 1065-1075, July 2022.
Experimental Dermatology
Polylysine dendrigraft is able to differentially impact Cutibacterium acnes strains preventing acneic skin
Experimental Dermatology, Volume 31, Issue 7, Page 1056-1064, July 2022.
Experimental Dermatology
Cytokine induced 3‐D organotypic psoriasis skin model demonstrates distinct roles for NF‐κB and JAK pathways in disease pathophysiology
Experimental Dermatology, Volume 31, Issue 7, Page 1036-1047, July 2022.